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The structure of swine vesicular disease virus (SVDV) was solved and refined at a 3.0-A˚ resolution by X-ray
crystallography to gain information about the role of sequence changes that occurred as this virus evolved from
the parental human pathogen coxsackievirus B5 (CVB5). These amino acid substitutions can be clustered in
five distinct regions: (i) the antigenic sites, (ii) the hydrophobic pocket of the VP1 -sandwich, (iii) the putative
CAR binding site, (iv) the putative heparan sulfate binding site, and (v) the fivefold axis. The VP1 pocket is
occupied by a branched pocket factor, apparently different from that present in the closely related virus CVB3
and in other picornaviruses. This finding may be relevant for the design of new antiviral compounds against
this site. Density consistent with the presence of ions was observed on the fivefold and threefold axes. The
structure also provided an accurate description of the putative receptor binding sites.
Swine vesicular disease virus (SVDV) is a member of the
Enterovirus genus, within the Picornaviridae family. It causes a
highly contagious disease of pigs that spreads rapidly by direct
contact among infected animals and by environmental contam-
ination (12). It is not a severe disease, although the similarity
between the lesions it causes and those produced by foot-and-
mouth disease (FMD) has led to it being considered econom-
ically important, and routine surveillance is maintained in Eu-
ropean countries (reviewed in reference 13). The disease was
first described in Italy in 1966 (38), and numerous outbreaks
have since occurred in Europe and Asia.
SVDV is a porcine variant of the human pathogen coxsack-
ievirus B5 (CVB5) (7, 20, 47, 23, 30, 54). The antigenic and
molecular relationships between these two viruses suggest that
SVDV is a genetic sublineage of CVB5 that evolved between
1945 and 1965, after the transfer of CVB5 from humans to pigs
(55).
Despite consisting of a single serotype, SVDV shows a high
genetic and antigenic variability. More than 100 SVDV isolates
from Europe and Japan have been characterized by analysis of
nucleotide sequences of the capsid proteins and by determin-
ing their antigenic profile. These isolates are classified in four
groups (6). Groups 1 and 2 are more closely related to each
other than the more recent groups 3 and 4, which may repre-
sent two independent SVDV introductions in Europe from
Asia, where SVDV strains have been isolated almost continu-
ally since 1970 (55). The fourth group includes viruses isolated
between 1987 and 1994 from Romania, The Netherlands, Italy,
and Spain.
The variability of SVDV also applies to its pathogenicity.
Nonpathogenic isolates cause a nonsymptomatic disease, while
virulent isolates produce typical lesions in infected pigs. Two
amino acid changes, located in positions 1132, within the EF-
loop of VP1 (The capsid residues are numbered with the first
digit indicating the viral protein) and 20 of the protease 2A,
have been shown to account for the differences in virulence
observed between the pathogenic J173 and the nonpathogenic
H7/376 SVDV isolates. The position 2A-20 appears to be the
dominant determinant (29) and acts by modifying the efficacy
of 2A to cleave the translation initiation factor eIF4GI, thus
affecting the cap-dependent protein synthesis (46). On the
other hand, the mechanism of attenuation underlying the sec-
ond determinant, located in the capsid at position 1132, re-
mains unknown.
Picornavirus particles are composed of 60 copies each of the
four capsid proteins VP1 through VP4, which enclose a single-
stranded messenger positive-sense RNA genome of about
7,400 nucleotides. Whereas VP1, VP2, and VP3 are exposed at
the viral surface, VP4 is in intimate contact with the RNA and
thus not accessible from the outer shell surface in the intact
virions. A prominent feature of the capsid surface in rhino- and
enteroviruses is a deep cleft around the fivefold axis of icosa-
hedral symmetry, called the canyon, which has been proposed
to be the receptor binding site for many picornaviruses (44).
This prediction was unequivocally demonstrated by cryo-elec-
tron microscopy (cryo-EM) for the major group rhinoviruses
and for enteroviruses, such as poliovirus and coxsackievirus,
that use receptors belonging to the immunoglobulin superfam-
ily (reviewed in reference 45). An additional structural feature
observed in all enteroviruses examined to date is a hydropho-
bic cavity, at the heart of VP1 beneath the canyon, that con-
tains cellularly derived lipids, known as “pocket factors,” which
would stabilize the virus during its spread from cell to cell and
would always be expelled upon interaction with the receptor.
Antiviral compounds have been discovered that bind tightly to
the VP1 pocket replacing the pocket factor and stabilizing the
capsids to such an extent that uncoating is blocked (1, 19, 48).
The main cellular receptor of coxsackie B viruses is the
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coxsackie- and adenovirus receptor (CAR), a 46-kDa mem-
brane glycoprotein (3, 36, 52) whereas decay-accelerating fac-
tor (DAF; also known as CD55), a ubiquitous phosphatidyl-
inositol anchored membrane protein regulating homologous
complement lysis, is also used as cellular coreceptor for CVB1,
CVB3, and CVB5 (3). SVDV retains the ability to bind CAR.
The oldest SVDV isolates seem able to infect human cells in a
similar way as the human homologue CVB5. The SVDV
UK-72 strain infects transfected CHO cells expressing human
CAR and human HeLa cells, and the infection is blocked by
both anti-human CAR and DAF antibodies (36). However, the
new SVDV isolate SPA/2/’93 has lost its ability to bind DAF,
although it retains the ability to bind CAR (M. A. Jimenez-
Clavero et al., unpublished data).
Little is known on the issue of SVDV receptor usage in
swine, its natural host, since neither porcine CAR nor porcine
DAF have been studied as possible receptors of SVDV. Inter-
estingly, it has recently been reported that the human coxsack-
ieviruses that use human DAF as receptor infect pig cells using
pig CAR but do not bind pig DAF in vitro (50).
On the other hand, there is evidence (E. Escribano-Romero
et al., unpublished data) that SVDV strongly interacts with
heparan sulfate (HS) proteoglycan (HSPG), an abundant com-
ponent of the cell surface. This interaction may represent a
first step in the process of binding of SVDV to cells, which, as
proposed for other HS binding viruses (17) may well involve an
initial attachment with HS, facilitating a second, interaction
with one receptor(s) mediating virus internalization.
The SVDV crystal structure, solved and refined to a 3.0-A˚
resolution, provides an accurate view of this new emerged
virus, serologically and phylogenetically related to CVB5. The
structure allowed mapping of the surface changes occurring
during the adaptation of CVB5 to infect pigs and provided
some details about the nature of an unusual lipid occupying the
hydrophobic pocket. An accurate description of the putative
receptor binding sites is also provided.
MATERIALS AND METHODS
Crystallization and data collection. SVDV (isolate SPA/2/’93) was prepared
and crystallized as described elsewhere (26). Three crystal forms were obtained
depending on the crystallization conditions. Orthorhombic crystals, with space
group I222 and unit cell parameters of a  318.3 A˚, b  349.9 A˚, and c  371.7
A˚, diffracted beyond a 3.0-A˚ resolution, were used for the structure determina-
tion presented in this work. A data set, with 70% completeness, was collected
using synchrotron radiation (ESRF Grenoble; beamlines ID14.4 and ID29) from
three crystals flash cooled to liquid-nitrogen temperature (Table 1). Crystals
were cryoprotected by soaking them for 1 min in a solution containing 30%
(vol/vol) glycerol in the crystallization buffer (1.2 M ammonium sulfate and 0.1
M sodium or potassium phosphate, pH 6.5 [26]). Diffraction images were pro-
cessed using the DENZO package (41).
Structure determination. Packing considerations indicated that the crystal cell
contained two SVDV particles. Hence, the centers of each particle occupied a
special 222 position, where three icosahedral twofold axes coincided with three
crystallographic axes. Therefore, the particles should be positioned in one of only
two possible orientations, which are related by 90° rotation around any of the
three orthogonal twofold axes. The proper positioning of the coordinates of
human CVB3 (37), used as a molecular model, gave an R-factor value of 38.4%
in the resolution range of 15 to 3.5 A˚.
The correctly oriented and positioned CVB3 model was used to calculate a set
of phases to a 3.5-A˚ resolution that were used as starting point for extensive
cycles of 15-fold averaging and phase extension with program DM (11). The
quality of the electron density map, at a 3.0-A˚ resolution, allowed the determi-
nation of most of the sequence and structural differences between SVDV and
CVB3 (Fig. 1). An atomic model was built into the 3.0-A˚ averaged density from
the SVDV amino acid sequence (GenBank accession no. AY157625) using the
graphic program O (27). The preliminary SVDV model was refined with the
programs X-PLOR (version 3.0; Yale University, New Haven, Conn.) and CNS
(8) using data from 20- to 3.0-A˚ resolution. The refined structure was used to
determine phases that were combined with the observed amplitudes to calculate
a new averaged electron density map. The last cycle of averaging had a corre-
lation coefficient of 93% and an R factor of 20%. In addition, 15-fold-averaged
2Fo-Fc and Fo-Fc difference maps were calculated at this stage using the pro-
gram GAP (J. M. Grimes and D. Stuart, unpublished data). The final maps
showed new structural features, in particular well-defined solvent molecules and
the accurate conformation of a number of side chains. Iterative positional and
B-factor refinement using CNS with noncrystallographic symmetry constraints
and bulk solvent correction was combined with manual model rebuilding. The
final R factor for the model was 23.5%, with 88% of the residues inside the most
favored region in the Ramachandran plot (Table 1). The program PROCHECK
(33) was used to monitor the geometry of the model at various stages in refine-
ment. An elongated electron density, bifurcated at one end, was observed in the
hydrophobic pocket of VP1 and modeled as a ceramide (Fig. 2). Fifty well-
ordered water molecules and six putative ions, five in the fivefold axis and one in
the threefold axis, were included in the final model (Table 1). The solvent
molecules were incorporated only when hydrogen bonded and the corresponding
electron density had the same level as neighbor protein residues. Coordinates
have been deposited in the Protein Data Bank (PDB code: 1MQT).
RESULTS AND DISCUSSION
Overall structure. The SVDV crystals used in this study
were orthorhombic and belonged to space group I222. The
crystallographic asymmetric unit contained one quarter of a
virus particle (26). The final molecular model includes 763
amino acid residues corresponding to viral proteins VP1, VP2,
VP3, and VP4; a ceramide located within the hydrophobic
pocket of VP1; 50 solvent molecules; and six ions in the five-
TABLE 1. Data collection and refinement statistics of SVDV
Parameter Value
Data collection
Dmin (A˚)................................................................................3.0
No. of crystals.......................................................................3
No. of reflections .................................................................459,326
No. of unique reflections ....................................................288,614
Rmerge (%) .........................................................................10.0 (19.1)a
Completeness (%) ...............................................................70 (51.0)a
Refinement
Data range (A˚).....................................................................30–3.0
No. of reflections [F  2 (F)]..........................................266,789
Rfactor (%) ..........................................................................23.5
Protein model
Residues............................................................................763
Atoms ................................................................................5,905
Nonprotein molecules
Water.................................................................................50
Pocket factor ....................................................................1
Ions ....................................................................................6
Myristic acid .....................................................................1
Rmsd from ideality for bonds (A˚).....................................0.012
Rmsd from ideality for angles (°)......................................1.9
Avg temp factors (A˚2)
All protein atoms.................................................................28.6
Main chain............................................................................28.5
Side chain .............................................................................28.7
Solvent molecules ................................................................38.8
Ions ........................................................................................35.0
Pocket factor ........................................................................48.6
Myristic acid .........................................................................66.7
a In brackets last resolution shell (3.1 to 3.0 A˚).
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fold and threefold axes (Table 1; see below). The quality of the
final averaged electron density maps at a 3.0-A˚ resolution
allowed the recognition of most of the SVDV amino acid
sequence without ambiguities (Fig. 1). Three protein regions
with poor density were not included in the present model: (i)
residues 1001 to 1012 at the N terminus of VP1, (ii) the eight
N-terminal residues of VP2, and (iii) residues 4011 to 4024 of
VP4. These three protein regions were poorly defined in most
picornaviral structures. Electron density was also weak for
residues 1130 to 1134 on the outside of the DE loop surround-
ing the icosahedral fivefold axis. The root mean square devia-
tions (RMSD) of the final model were 0.012 A˚ and 1.9° with
respect to the ideal bond lengths and angles, respectively (Ta-
ble 1). The main chain conformational angles are located
within or in the close vicinity of the energetically most favored
regions of the Ramachandran plot.
The SVDV structure determined is, as expected, closely
related to that described for other enteroviruses. The con-
served -sandwich motif, observed in all picornaviruses, is well
preserved in SVDV proteins VP1, VP2, and VP3. The most
similar virus to SVDV, of known three-dimensional structure,
is CVB3 (37). The RMSD for the superimposition of C atoms
from 751 structurally equivalent residues in the two viruses is
only 0.41 A˚. A high structural similarity was also found be-
tween SVDV and CVA9 (22) or echovirus 1 (15), with RMSD
values of only 0.57 and 0.59 A˚, respectively, matching 751
residues in both superimpositions. Structural similarity is lower
between SVDV and other enteroviruses such as poliovirus
(14), with a RMSD for the C atoms from the -sandwiches of
0.98 A˚.
The structure of the external loops connecting the -strands
always shows larger differences. In particular, the BC and DE
loops of VP1 and the EF loop of VP2 differ from those of the
CVB3 mostly in structure (Fig. 1; see below).
Like all other picornaviruses, SVDV has a myristic acid,
covalently attached to the N-terminal glycine of VP4 (10). The
myristoyl groups cluster around the fivefold axis just below the
N-terminal VP3 -cylinder.
Five peaks of ion-like electron density were found along the
icosahedral fivefold axis. These peaks, approximately 80% of
the height of the surrounding protein density, appear to make
water-mediated interactions with polar residues on the DE and
EF loops of VP1. The disposition of these putative ions is
essentially coincident to that found in CVA9 (22). Additional
spherical density, twice the height of the surrounding protein
density, was also detected on the icosahedral threefold axis.
The putative cation would coordinate with the side chain ox-
ygen O1 from three symmetry-related D3203 and with three
water molecules at a distance of 2.3 and 2.6 A˚, respectively.
The cations on the fivefold and threefold axes have been de-
FIG. 1. Stereo views comparing two external loops from SVDV (black) with the corresponding regions in CVB3 (white). (A) The BC loop of
VP1 that contributes to antigenic site 1 in SVDV (residues 1080 to 1090) is three residues longer and more exposed than the corresponding
segment of CVB3. (B) The EF loop of VP2 (residues 2156 to 2166) that contributes to antigenic site 2 is two residues shorter in SVDV than the
corresponding loop of CVB3. The two averaged 2Fo-Fc maps covering the BC loop and -knob regions are shown as chicken boxes.
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scribed elsewhere for other picornaviruses (22, 35, 37, 56).
These ions may be involved in the regulation of capsid stability.
Mapping the structural changes in the transition CVB5 to
SVDV. Multiple sequence alignments between SVDV strains
representing the four antigenic groups and the parental CVB5
revealed a number of amino acid changes on the viral surface
during the evolution of CVB5 to SVDV. Isolate SPA/2/’93,
which belongs to antigenic group 4 of SVDV showed 39 amino
acid changes in structural proteins with respect the parental
CVB5 (Table 2; Fig. 3). Thirteen of these changes were ob-
served between SPA/2/’93 and the oldest SVDV strains (Table
2), some of which may be linked to the loss of the ability of
SPA/2/’93 to bind DAF. However, most of these changes oc-
curred in regions of considerable variation among SVDV iso-
lates and map into an extended surface area, which compli-
cates the localization of the DAF binding region.
The structure shows that with the exception of three changes
(at positions 1046, 2040, 3006, and 3035) which are located at
the capsid interior, the position of all of the amino acid sub-
stitutions mapped on the surface of the virion and was clus-
tered in five well-defined regions (Fig. 3; Table 2).
(i) The antigenic sites. The antigenic structure of SVDV has
been examined by monoclonal antibody-resistant mutant anal-
ysis (5, 28, 40). Seven neutralization sites have been defined,
five of which (1, 2A, 2B, 3A, 3B, and 3C) are analogous to
those described for poliovirus, the type species for the entero-
virus group (28). The other two are new and specific for iso-
lates of the most recent antigenic group of SVDV (group 4) (5,
40). The seven antigenic sites of SVDV can now be positioned
on the corresponding capsid structure and compared with the
arrangement of epitopes found in other picornaviruses (Fig. 3).
Fifteen of the 33 amino acid changes found in the CVB5-
SVDV comparison (Table 2; Fig. 3) mapped at the external
loops containing the antigenic sites described in the following
paragraphs.
Amino acid residues D1083 and S1084 were located within
the BC loop of VP1. This loop flanks the north rim of the
canyon closest to the fivefold axis and is particularly variable in
FIG. 2. Stereo views of the hydrophobic pocket of VP1 and the pocket factor. (A) Averaged Fo-Fc map showing the branched electron density
corresponding to a putative pocket factor that was interpreted as a ceramide. VP1 residues in the vicinity of the pocket are explicitly shown.
(B) Superimposition of the ceramide molecule identified in the structures of SVDV (solid balls and sticks), the palmitic acid of the CVB3 structure
(open balls and sticks) and the two WIN51711 molecules found in the structure of CVA9 (thin lines). The sphingosine moiety of the ceramide
superimposes on the palmitic acid of CVB3 and one of the WIN51711 molecules. The fatty acid linked to the sphingosine moiety is partially
coincident with the second WIN51711 molecule.
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both length and sequence among picornaviruses. In SVDV, it
is two residues longer and more exposed than the equivalent
one in CVB3 (Fig. 1). The BC loop contains a relevant anti-
genic site for enteroviruses and rhinoviruses. In particular,
residues D1083 and S1084 are frequently substituted in mu-
tants escaping neutralization by monoclonal antibodies and
contributed to define antigenic site 1 (5) (Fig. 3), which is
conserved in all the four antigenic groups of SVDV, including
the oldest isolate, IT66 (5, 28, 40).
Most substitutions in VP2 (Table 2) map on the largest and
most variable loop of this protein, the puff or EF loop. The
SVDV puff consists of two loops. The first loop (residues 2130
to 2154) lies on the rim of the canyon closest to the twofold
axes and contains the antigenic site 2B in SVDV (28, 40). The
substituted residues P2143 and K2148 map within this region.
The second loop (amino acids 2155 to 2170; Fig. 1) points to
the outer viral surface. Replaced residues S2160 and E2163 are
located within this loop, which contains the antigenic site 2A
(5, 28, 40).
The substituted amino acids E3062 and M3063 are located
at the center of the VP3 “knob,” which is the major surface
protrusion of VP3. This region, together with the VP1 C-
terminal residues 1272 and 1275 define the antigenic site 3A
(28, 40). The changes at residues S1273 and T1279 map close
to this antigenic region (Fig. 3). The neutralizing immunogenic
site 3B, consisting of residues within the BC loop of VP3 and
the C-terminal end of VP2, includes residues P3076 and
A2233, respectively, the latter being substituted only in the
SVDV strains that appeared after 1972 (Table 2). The last VP3
residue substituted N3235 is located at the carboxyl terminus
of the protein that contains the antigenic site 3C (Fig. 3).
The amino acid K1258 (Table 2), near the VP1 C termini,
maps on the antigenic site IV (Fig. 3). This epitope is specific
for isolates of the most recent antigenic group of SVDV (5). In
TABLE 2. Amino acid changes occurring in the capsid proteins VP1, VP2, and VP3, during the SVDV evolutiona
Residue
Amino acid
Location
SVDVrecent SVDVold CVB5 CVB3
1045 S S A A N-terminus of VP1; virus interior
1083 D D G G B-C loop of VP1 (antigenic site 1)
1084 S S T A B-C loop of VP1 (antigenic site 1)
1096 A T T P Hydrophobic pocket of VP1
1131 T V/I V T 5-fold axis; VP1 D-E loop
1136 T S S A 5-fold axis; VP1 D-E loop
1175 N S S N 5-fold axis; VP1 E-F loop
1180 M M I M Hydrophobic pocket of VP1
1186 G G S S Hydrophobic pocket of VP1
1200 R R K E Putative CAR binding site
1210 S S N N Putative CAR binding site
1225 G/Sb D D A 5-fold axis; H-I loop of VP1
1227 G G S S 5-fold axis; H-I loop of VP1
1258 K/Eb Q Q E Antigenic site IV/putatative HS binding site
1266 I/Vb E/K E Q Putative HS binding site
1269 S G G G Putative HS binding site
1273 S S G T C-terminus of VP1 (antigenic site 3A)
1279 T T A T C-terminus of VP1 (near site 3A)
1281 K/Rb K/R Q T C-terminus of VP1 (near site 3A)
2040 A T T D N-terminus of VP2. Virus interior
2075 G S S T B-C loop of VP2
2143 P P Q S E-F loop of VP2 (near site 2B)
2148 K K N G E-F loop of VP2 (near site 2B)
2151 I I T T E-F loop of VP2 (antigenic site 2B)
2153 S N N K E-F loop of VP2 (antigenic site 2B)
2160 S S T S E-F loop of VP2 (antigenic site 2A)
2163 E E Q N E-F loop of VP2 (antigenic site 2A)
2233 A T T P H-I loop of VP2 (antigenic site 3B)
3006 A S L N N-terminus of VP3; virus interior
3035 D D A N N-terminus of VP3; virus interior
3062 E V V T -B knob (antigenic site 3A)
3063 M M S N -B knob (antigenic site 3A)
3076 P P A E B-C loop of VP3 (antigenic site 3B)
3088 T T I Q Putative CAR binding site
3092 N N S S Putative CAR binding site
3108 A A T T Canyon floor, protomer interphase
3181 M M V S Putative CAR binding site
3204 A A T A H-I loop of VP3
3235 N N S N C-terminus of VP3 (antigenic site 3C)
a List of sequence changes identified from a multiple alignment computed with program ClustalW (52) of several SVDV isolates together with CVB5 and CVB3.
The available crystallographic information from CVB3 (38) and SVDV SPA/2/93 (this study) was also taken into account. Old SVDV (column three) includes isolates
from 1966 to 1972. Recent SVDV (column two) includes isolate SPA/2/93 and other post-1972 strains. Sequence differences between old and recent SVDV strains
are shown in boldface type.
b Strain that differs from the Spanish strain.
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addition, it may be associated with the ability of SVDV to bind
HS (see below).
All neutralization sites identified by monoclonal antibody-
resistant mutant analyses are predicted to be exposed on the
surface of the capsid (5, 28, 40). However, sera from SVDV-
infected pigs recognize other epitopes that are located in the
capsid but not exposed on its surface (24). According to a
widely accepted model, the capsids of entero- and rhinoviruses
undergo conformational rearrangements upon virus binding to
the cell receptor (16). In this process, the capsid transforms
into a structurally and antigenically altered form, the A parti-
cle. These conformationally altered particles undergo two spe-
cific changes, namely, the externalization of the N terminus of
VP1 and the loss of VP4 (2, 16). This transition is an essential
event in the mechanism of infection of many picornaviruses as
it was well illustrated by the fact that antiviral drugs that inhibit
FIG. 3. (A) Ribbon diagram showing the secondary structural elements of a viral protomer of SVDV (VP1, light blue; VP2, light green; VP3,
pink). The location of the amino acid changes between CVB5 and SVDV (SPA/2/’93) is shown as differently colored spheres and explicitly
indicated. (B) Space-filling model of an SVDV pentamer subunit showing the disposition of substitutions on the external part of the capsid colored
as in A. (C) Ribbon diagram of an SVDV protomer highlighting the amino acids contributing to the seven antigenic sites residues as different
colored spheres and explicitly indicated. (D) Space-filling model of an SVDV pentamer subunit showing the disposition of the antigenic sites
colored as in C.
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a broad range of entero- and rhinoviruses (1) act by stabilizing
native virus capsids, thus preventing these conformational
changes (19, 34, 53). The relevance of the immune response to
the VP1 N terminus for host protection against poliovirus has
been pointed out by in vitro studies of viral neutralization using
synthetic peptides (9). In addition, this region is immunogenic
in humans vaccinated with an attenuated (Sabin) poliovirus
vaccine (43), in rabbits inoculated with CVA9 (42), and in
SVDV infected pigs (24). The substituted residue S1045 maps
to this region (Table 2). It has been shown that an epitope
within this region, residues 1005 to 1018 become exposed upon
viral attachment to the cell surface and that in this conforma-
tion the virus can be neutralized with antibodies directed
against this epitope (25).
(ii) The VP1 hydrophobic pocket. Amino acid residues
A1096, M1180, and G1186 (Table 2) map to the hydrophobic
pocket, inside the -barrel of VP1 which is often occupied by
lipids of various length depending on the pocket size. In fact,
the structure of SVDV showed a portion of elongated extra
density, bifurcated near the entrance filling most of the pocket
(Fig. 2). This extra density was only slightly weaker than that
corresponding to the surrounding protein residues, suggesting
that the putative pocket factor was present with a high occu-
pancy. The size and shape of the density in the SVDV structure
largely differed from the density of the CVB3 structure, which
was interpreted as palmitic acid (37). The shape of the electron
density and the environment around the polar end may be
consistent with the tentative identification of a branched sphyng-
olipid modeled as a ceramide. Sphingosine has been previously
identified as binding the pocket of polioviruses 1 and 3 (14).
However, a single sphingosine molecule would not account for
all the density observed in the SVDV structure (Fig. 2A). The
orientation of the sphingosine moiety in SVDV is the same as
that observed for the palmitic acid in CVB3 and for the sphin-
gosine in polioviruses. In turn, the aliphatic tail of the 8-carbon
fatty acid linked to the sphingosine runs near to the pocket
entrance, but making contacts only with the hydrophobic side
chains of the protein (Fig. 2). The polar head group of the lipid
forms very precise stabilizing interactions with the virus; The
fatty acyl oxygen contacts the main chain nitrogen of N1212
and the amide nitrogen is hydrogen bonded to the main chain
oxygen of S1192. Finally, the hydroxyl group of the sphingosine
moiety interacts with the side chain of R1097 (Fig. 2).
The dimensions of the hydrophobic pocket are comparable
in both the SVDV and CVB3 structures, the two major differ-
ences being an alanine at position 1096 instead of a proline and
a glycine, instead of a serine, at residue 1186. Both substitu-
tions represent a small increment in the pocket size and in the
hydrophobicity in the pocket entrance, which favors the pres-
ence of a larger pocket factor in SVDV. The structure shows
the first identification of a branched lipid in the hydrophobic
pocket of a picornavirus and may be relevant for the design of
antiviral compounds to bind here. A similar situation has been
described for the structure of CVA9 complexed to the antiviral
drug WIN51711 (22), where two drug molecules were found
together filling the VP1 pocket and the location of the second
WIN molecule was partially coincident with the second branch
of the lipid found in SVDV (Fig. 2).
The fact that the pocket can be occupied by lipids of various
lengths and shapes in closely related viruses suggests that these
viruses show different preferences for cell-specific membrane
components. The apparent selectivity of pocket factors by spe-
cific picornaviruses may be a factor, in addition to the cellular
receptor, determining the tissue tropism of the virus (22, 49).
(iii) The putative CAR binding site. Replaced residues
R1200, S1210, at the GH loop of VP1 and N3092 and M3181,
located at the BC and GH loops of VP3, respectively (Table 2;
Fig. 3), map at the base of the canyon which is the CAR
binding site of CVB3 (21). In addition, the amino acid residues
K1281 at the C termini of VP1 and E2163 within the EF loop
of VP2 (Table 2) lie next to or within the CAR binding site, as
revealed by the cryo-EM structure of the complex CVB3-CAR
(21). The structure of this complex showed several charged
residues lining the binding interface that make complementary
interactions with CAR. The putative footprint of CAR on the
surface of SVDV can be predicted after superimposition of the
CVB3-CAR structure on the SVDV structure (Fig. 4A and B).
Comparison of both footprints revealed moderate conserva-
tion of residues on the CAR recognition site in the two viruses.
The distribution of hydrophobic and hydrophilic amino acids
in the footprint areas is similar in both viruses, and the nega-
tively charged area in the canyon floor (residues D3182,
E3183) is mostly conserved (Fig. 4A and B). The main differ-
ence between the CVB3 and SVDV CAR footprints is the
presence of a negatively charged residue at position 2163 of
SVDV instead of a neutral one in CBV3. It has been reported
that a variant of CVB3 with the mutation N2165-D attenuates
the myocarditic phenotype (31). This mutation, adjacent to
K2166 may affect the electrostatic interactions between this
residue in CVB3 and two acidic residues within the BC loop of
CAR (21). In addition, the parental CVB5 shows a glutamine
in position 2163. In the projected SVDV CAR footprint, po-
sition 2166 is replaced by a threonine (Fig. 4B). Nevertheless,
the electrostatic interaction between CVB3 and the acidic BC-
loop of CAR may be maintained in SVDV by a slightly differ-
ent orientation of the D1 domain of CAR onto the SVDV
surface. A similar situation has been described in the interac-
tions between the major group HRVs 14 and 16 with ICAM-1
(32). These hypotheses are consistent with the conserved CAR
binding activity of SVDV strains (36).
(iv) The putative HS binding site. Three amino acid substi-
tutions (positions 1258, 1266, and 1269) located near the C
terminus of VP1 were detected between the oldest SVDV
strains, isolates from 1966 to 1972, and the more recently
isolated viruses (Table 2). All three substitutions may be re-
lated to the ability of SVDV SPA/2/’93 to bind HS. The use of
HSPGs as receptors for initial cell contact of SVDV has been
recently investigated (Escribano-Romero et al., unpublished
data). The binding of SVDV to glycosaminoglycans was estab-
lished by heparin-affinity chromatography as well as by inhibi-
tion of the virus infection, either by treatment with soluble HS
or by enzymatic digestion of cell surface glycosaminoglycans.
In addition, the analysis of heparin resistant SVDV mutants
allowed the localization of the putative HS binding site. The
amino acid sequences of the mutants revealed the same two
substitutions in all SVDV variants analyzed: VP1 I12663K
and VP2 A21553V. The structure of SVDV shows that both
substitutions are close to each other and adjacent to a region of
positively charged residues, characteristic of the heparin-bind-
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ing domains of proteins. Three lysines K1253, K1258, and
K1259 at the C termini of VP1 and one arginine R3073 at the
BC loop of VP3 contributed to this region (Fig. 4C). The
crystal structure of FMD virus (FMDV) serotype O in complex
with HS (17) showed the HS binding site of the virus in a
shallow depression of positively electrostatic charge on the
virion surface contributed by the three capsid proteins VP1,
VP2, and VP3 (Fig. 4D). The predicted HS binding site of
FIG. 4. The putative receptor binding sites in SVDV SPA/2/’93 (A) Roadmap diagram of the CAR footprint on the surface of CVB3 (PDB
code 1JEW) (22). On the top is an icosahedral asymmetric unit with the footprints shown as grey shadows and the limits of the canyon shown as
black outlines. On the bottom are residues defining the CAR footprint. Basic amino acids are shown in blue, acidic amino acids are shown in red,
hydrophobic amino acids are shown in green, and polar amino acids in yellow. (B) Projected footprint of CAR on the SVDV surface after
superimposition of the cryo-EM structure of the CVB3-CAR complex on the crystal structure of SVDV. Coloring and top-bottom representations
as in A. (C) Electrostatic accessible surface representation for the biological protomer of SVDV calculated with GRASP (39). The electrostatic
potential with positive charge was colored in blue and that with negative charge in red. The position of the residues (I1266 and A2135) substituted
in all SVDV mutants lacking the ability to bind heparin are indicated in green. These residues are adjacent to a region of positively electrostatic
charge, the candidate to be the HS binding site in SVDV. The basic residues R1236 and K1080 which would define a second putative binding site
for HS proteoglycans near the fivefold axis are indicated in yellow. (D) Electrostatic accessible surface representation for the biological protomer
of FMDV type O in complex, with HS (PDB entry code 1QQP) (17) shown for comparison. The bound HS molecule (represented by sticks) is
located within a slight depression of positively charged residues making contacts with all three major capsid proteins. The FMDV and SVDV capsid
surfaces differ from each other both in shape and in charge distributions. This may explain why the predicted HS binding site of SVDV does not
overlap the FMDV HS binding site.
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SVDV maps near, but does not overlap the FMD virus HS
binding site (Fig. 4C and D).
(v) Fivefold axis. The substituted residues T1131, T1136,
N1175, S1225, and G1227 form part of three loops of VP1
(DE, FG, and HI) that cluster at the fivefold axis and the
particular amino acids T1136 and N1175 participate in inter-
actions with two of the putative cations located along this axis.
The VP1 DE loop (sequence 1125TQEQSTTQGQDTP1137) is
the most prominent of the exterior loops about the fivefold axis
and the residues at the base of the loop make extensive inter-
actions with its icosahedral fivefold symmetry related DE
loops. Because of the extensive protein-protein and protein-
ion interactions, the DE loop may contribute to the stabiliza-
tion of the virus pentamers and be partially responsible for the
stability of the SVDV virions. In addition to the stabilizing role
of the DE loop, the residue Q1132 is involved, at least in part,
in the expression of pathogenic versus nonpathogenic pheno-
types of SVDV (29). This loop was partially disordered in the
X-ray structure (residues from 1130 to 1134 presented poor
electron density). A similar situation has been described in the
equivalent loop of the closely related CVB3, where two amino
acids within this loop are disordered (37). It appears that the
external part of the DE loop is flexible and can adopt more
than one conformation. The flexibility of the loops surrounding
the fivefold pore seems to contribute, at least in part, to the
stability of the virus pentamers. The higher virulence observed
in SVDV strains that show the substitution Q3G at position
1132 may be due to an increment in flexibility of the DE loop
and thus in the stability of SVDV virions.
The third loop running close to the fivefold axis that contains
the replaced residues S1225 and G1227 is the HI-loop of VP1
(Table 2; Fig. 3) This loop, together with the DE and HI loops
of a neighbor protomer within a pentamer and the C terminus
of VP3 define a small depression on the SVDV surface that
was partially filled by a nonidentified electron density. We
failed to identify the chemical moiety of this feature. The
density may be due to a tight cluster of water molecules, but its
general shape together with the lack of hydrogen bond inter-
actions in the region is not consistent with it being solvent. Or
else the density may be due to the presence of sucrose mole-
cules from the purification process that occupy the crevice. The
presence of three positively charged residues (K1081, R1136
and R1221 from a neighboring protomer) flanking the cavity
suggest a second binding site for HSPGs within this region
(Fig. 4).
Conclusions. The structure of SVDV strain SPA/2/’93 de-
termined at a 3.0-A˚ resolution allowed us to interpret most of
the amino acid changes that take place in the evolution of
CVB5 to SVDV. These changes are distributed into five re-
gions: (i) the antigenic sites, (ii) the hydrophobic pocket of the
VP1 -sandwich, (iii) the putative CAR binding site, (iv) the
putative HS binding site, and (v) the fivefold axis. The last
three regions may be related with the adaptation of the virus to
bind the porcine receptors and to the SVDV capsid stability.
The finding of a branched lipid occupying the hydrophobic
pocket of VP1, apparently different from that found in other
picornaviruses, offers great potential for the design of new
antiviral compounds against this site.
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ADDENDUM
The structure of SVDV strain UKG/27/72 was reported
while this paper was under review (18). Our structure confirms
and extends the main conclusions reported there.
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